Radiographic Findings and other Predictors in Adults with Covid-19

Li, Kaiyan; Chen, Dian; Chen, Shengchong; Feng, Yuchen; Chang, Chenli; Wang, Zi; Wang, Nan; Zhen, Guohua

doi:10.1101/2020.03.23.20041673

Cited by 31 publications

(38 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17][18][19][20][21][22][25][26][27][28]31 (Figure 3(a)) in 16 studies. [11][12][13][14]16,18,19,[21][22][23][25][26][27][28]31,34 (Figure 4(a)). [16][17][18][19][20][21][22][23][25][26][27]31 Figure 5) in 10 studies.…”

Section: Elevated Crp and Outcomementioning

confidence: 98%

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Huang

Pranata

Lim

et al. 2020

Ther Adv Respir Dis

512

438

View full text Add to dashboard Cite

Background: Patients critically ill with coronavirus disease-2019 (COVID-19) feature hyperinflammation, and the associated biomarkers may be beneficial for risk stratification. We aimed to investigate the association between several biomarkers, including serum C-reactive protein (CRP), procalcitonin (PCT), D-dimer, and serum ferritin, and COVID-19 severity. Methods: We performed a comprehensive systematic literature search through electronic databases. The outcome of interest for this study was the composite poor outcome, which comprises mortality, acute respiratory distress syndrome, need for care in an intensive care unit, and severe COVID-19. Results: A total of 5350 patients were pooled from 25 studies. Elevated CRP was associated with an increased composite poor outcome [risk ratio (RR) 1.84 (1.45, 2.33), p < 0.001; I2: 96%] and its severe COVID-19 (RR 1.41; I2: 93%) subgroup. A CRP ⩾10 mg/L has a 51% sensitivity, 88% specificity, likelihood ratio (LR) + of 4.1, LR- of 0.5, and an area under curve (AUC) of 0.84. An elevated PCT was associated with an increased composite poor outcome [RR 3.92 (2.42, 6.35), p < 0.001; I2: 85%] and its mortality (RR 6.26; I2: 96%) and severe COVID-19 (RR 3.93; I2: 63%) subgroups. A PCT ⩾0.5 ng/ml has an 88% sensitivity, 68% specificity, LR+ of 2.7, LR- of 0.2, and an AUC of 0.88. An elevated D-dimer was associated with an increased composite poor outcome [RR 2.93 (2.14, 4.01), p < 0.001; I2: 77%], including its mortality (RR 4.15; I2: 83%) and severe COVID-19 (RR 2.42; I2: 58%) subgroups. A D-dimer >0.5 mg/L has a 58% sensitivity, 69% specificity, LR+ of 1.8, LR- of 0.6, and an AUC of 0.69. Patients with a composite poor outcome had a higher serum ferritin with a standardized mean difference of 0.90 (0.64, 1.15), p < 0.0001; I2: 76%. Conclusion: This meta-analysis showed that an elevated serum CRP, PCT, D-dimer, and ferritin were associated with a poor outcome in COVID-19. The reviews of this paper are available via the supplemental material section.

show abstract

Section: Elevated Crp and Outcomementioning

confidence: 98%

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Huang

Pranata

Lim

et al. 2020

Ther Adv Respir Dis

512

438

View full text Add to dashboard Cite

show abstract

“…30 studies were included in the qualitative synthesis and meta-analysis [ Figure 1]. [3,8,[17][18][19][20][21][22][23][24][25][26]9,[27][28][29][30][31][32][33][34][35][36][10][11][12][13][14][15][16] There were a total of 6452 patients from 30 studies.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Huang

Lim

Pranata

2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

806

747

View full text Add to dashboard Cite

Background and AimsDiabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 . We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia. MethodsSystematic literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression. ResultsThere were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88,3.03], p<0.001; I 2 : 62%) and its subgroup which comprised of mortality (RR 2.12 [1.44, 3.11], p<0.001; I 2 : 72%), severe COVID-19 (RR 2.45 [1.79, 3.35], p<0.001; I 2 : 45%), ARDS (RR 4.64 [1.86,11.58], p=0.001; I 2 : 9%), and disease progression (RR 3.31 [1.08, 10.14], p=0.04; I 2 : 0%). Meta-regression showed that the association with composite poor outcome was influenced by age (p=0.003) and hypertension (p<0.001). Subgroup analysis showed that the association was weaker in studies with median age ≥55 years-old (RR 1.92) compared to <55 years-old (RR 3.48), and in prevalence of hypertension ≥25% (RR 1.93) compared to <25% (RR 3.06). Subgroup analysis on median age <55 years-old and prevalence of hypertension <25% showed strong association (RR 3.33) ConclusionDM was associated with mortality, severe COVID-19, ARDS, and disease progression in patients with COVID-19.

show abstract

“…The characteristics of the enrolled studies are listed in Table 1. (6)(7)(8)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) Information on the study location, sample size, age, sex, clinical outcome, PT, INR, and levels of TBIL, DBIL, ALT, AST, GGT, ALP, ALB, and GLB was recorded. The mean ages of the patients with COVID-19 who were discharged alive and died were 56.4 and 68.7 years, respectively (Supporting Fig.…”

Section: Characteristics Of the Studies Included In The Meta-analysismentioning

confidence: 99%

Liver Chemistries in Patients With COVID‐19 Who Were Discharged Alive or Died: A Meta‐analysis

Xing

Xuan²,

Ren³

et al. 2020

Hepatol. Commun.

View full text Add to dashboard Cite

Although abnormal liver chemistries are linked to a higher risk of coronavirus disease 2019 (COVID-19)-related death, liver manifestations may be diverse and even confusing. Thus, we performed a meta-analysis of published liver manifestations and described the liver damage in patients with COVID-19 who died or discharged alive. We searched PubMed, Google Scholar, medRxiv, bioRxiv, the Cochrane Library, Embase, and three Chinese electronic databases through April 22, 2020. We analyzed pooled data on liver chemistries stratified by the main clinical outcome of COVID-19, using a fixed or random-effects model. In our meta-analysis of 19 studies, which included a total of 4,103 patients, the pooled mean alanine aminotransferase and aspartate aminotransferase levels were, respectively, 31.7 IU/L and 51.0 IU/L in the patients with COVID-19 who died and 27.7 IU/L and 32.9 IU/L in those discharged alive (both P < 0.0001). Compared with the patients discharged alive, those who died tended to have lower albumin levels but longer prothrombin time and higher international normalized ratio. Conclusion: In this meta-analysis, according to the main clinical outcome of COVID-19, we comprehensively describe three patterns of liver impairment related to COVID-19: hepatocellular injury, cholestasis, and hepatocellular disfunction. The patients who died from COVID-19 tended to have different liver chemistries from those discharged alive. Special caution should be given to the patients with a relatively higher index of liver chemistries. (Hepatology Communications 2020;0:1-12). C oronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a nonsegmented positive-sense RNA virus with an envelope belonging to the family Coronaviridae. The coronavirus is widely distributed in humans and other mammals. In the past 20 years, the coronavirus has caused several localized epidemics and even global pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the ongoing COVID-19 pandemic. Worldwide, the spread and upward trend of COVID-19 have accelerated dramatically. According to the situation report released by the World Health Organization (WHO), as of April 25, 2020, 2,719,897 COVID-19 cases were confirmed globally, with a fatality rate of 6.9%. (1) In response to the emerging threat, the WHO declared a Public Health Emergency of International Concern

show abstract

Radiographic Findings and other Predictors in Adults with Covid-19

Cited by 31 publications

References 3 publications

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Liver Chemistries in Patients With COVID‐19 Who Were Discharged Alive or Died: A Meta‐analysis

Contact Info

Product

Resources

About